ArQule to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Disease Companies on September 24, 2019
September 17 2019 - 7:00AM
Business Wire
ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci,
Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical
Officer and Head of Research and Development, will participate in
the Oppenheimer Fall Summit Focused on Specialty Pharma and Rare
Disease Companies on Tuesday, September 24, 2019 at The Parker New
York Hotel in New York City.
About ArQule
ArQule is a biopharmaceutical company engaged in the research
and development of targeted therapeutics to treat cancers and rare
diseases. ArQule’s mission is to discover, develop and
commercialize novel small molecule drugs in areas of high unmet
need that will dramatically extend and improve the lives of our
patients. Our clinical-stage pipeline consists of four drug
candidates, all of which are in targeted, biomarker-defined patient
populations, making ArQule a leader among companies our size in
precision medicine. ArQule’s pipeline includes: ARQ 531, an orally
bioavailable, potent and reversible dual inhibitor of both wild
type and C481S-mutant BTK, in phase 1 for patients with B-cell
malignancies refractory to other therapeutic options; miransertib
(ARQ 092), a potent and selective inhibitor of the AKT
serine/threonine kinase, in a planned registrational trial with
cohorts in Proteus syndrome and PROS to initiate in 2019; ARQ 751,
a next generation highly potent and selective AKT inhibitor, in
phase 1 for patients with AKT1 and PI3K mutations; and
derazantinib, a multi-kinase inhibitor designed to preferentially
inhibit the fibroblast growth factor receptor (FGFR) family, in a
registrational trial for iCCA in collaboration with Basilea and
Sinovant. ArQule’s current discovery efforts are focused on the
identification and development of novel kinase inhibitors,
leveraging the Company’s proprietary library of compounds.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190917005155/en/
Corporate Contact: Kathleen Farren Investor Relations
& Executive Assistant to the CFO ir@arqule.com
Media Contact: Cait Williamson, Ph.D. LifeSci Public
Relations (646) 751-4366 cait@lifescipublicrelations.com
www.ArQule.com
ArQule (NASDAQ:ARQL)
Historical Stock Chart
From Aug 2024 to Sep 2024
ArQule (NASDAQ:ARQL)
Historical Stock Chart
From Sep 2023 to Sep 2024